ACADIA Pharmaceuticals Inc. filed its quarterly report on Form 10-Q with the SEC for the period ended June 30, 2026, disclosing net product sales growth, continued net income, and an expanded balance sheet compared to year-end 2025.

Key Highlights

  • Q2 2026 net product sales: $307,959 thousand, up from $264,566 thousand in Q2 2025.
  • Six-month net income: $35,137 thousand for the six months ended June 30, 2026, compared to $45,653 thousand in the same period of 2025.
  • Diluted EPS: $0.18 for Q2 2026 and $0.20 for the first six months of 2026, per the filing.
  • Total assets: $1,742,900 thousand as of June 30, 2026, up from $1,564,195 thousand at December 31, 2025.
  • Cash and cash equivalents: $384,985 thousand at June 30, 2026, compared to $177,695 thousand at December 31, 2025.
  • Accumulated deficit reduced: from $1,813,386 thousand at December 31, 2025 to $1,778,249 thousand at June 30, 2026.
  • Shares outstanding: 172,305,518 shares of common stock as of July 28, 2026, according to the filing.

ACADIA Pharmaceuticals Q2 2026: Revenue Growth and Balance Sheet Expansion

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a Delaware-incorporated biopharmaceutical company headquartered in San Diego, California, reported net product sales of $307,959 thousand for the three months ended June 30, 2026, according to the filing. This compares to $264,566 thousand in the same quarter of 2025. For the six-month period, net product sales totaled $576,021 thousand, versus $508,882 thousand in the first half of 2025. Total revenues equaled net product sales in both periods, the company disclosed.

Operating expenses for the second quarter of 2026 were $270,123 thousand, including cost of product sales of $28,316 thousand, research and development expenses of $81,555 thousand, and selling, general and administrative expenses of $160,252 thousand. Income from operations for Q2 2026 was $37,836 thousand. Net income for the quarter was $31,500 thousand, and income tax expense was $14,973 thousand, the filing stated. For the six months ended June 30, 2026, net cash provided by operating activities was $134,762 thousand, up from $84,279 thousand in the comparable prior-year period.

On the balance sheet, total stockholders' equity increased to $1,306,609 thousand at June 30, 2026, from $1,227,390 thousand at December 31, 2025. The accumulated deficit narrowed to $1,778,249 thousand from $1,813,386 thousand over the same interval, reflecting the net income generated in the period. Investment securities available-for-sale stood at $571,489 thousand, and total liabilities were $436,291 thousand, per the filing. Stock-based compensation for the six-month period was $31,638 thousand as reported in the cash flow statement.

What Was Disclosed

ACADIA Pharmaceuticals filed its Form 10-Q for the quarter ended June 30, 2026, reporting higher net product sales year-over-year, positive net income, increased cash balances, and growth in total assets relative to December 31, 2025.